Minding the Gap Rheumatoid Arthritis Advances From London 2016

Disclaimer

Program Goal

Segment 1: Michael Schiff Abstracts Reviewed

Segment 2: Roy Fleischmann Abstracts Reviewed

Segment 3: Roy Fleischmann Abstracts Reviewed

Concluding Remarks

New TNF Inhibitor Formulations and Delivery Methods

Abstract #1

Study Design

Immediate Pain After Injection

Impact of Findings

Abstract #2

Study Design

Autoinjection Device Ranking by Patient Preference

Impact of Findings

Biologic Dose Reductions in Patients with RA

Abstract #1

Study Design[a]

Physical Function and % Patients With Normative Function From Wk 52 to Wk 104

Conclusion

Abstract #2

Study Design[a]

Reasons for Dose Reduction in EXTEND

Conclusions

Effect of Biologic Agents on RF and ACPA Levels

Abstract #1

Study Design[a]

OPTIMA Change in RF and ACPA with Adalimumab Treatment

Validating Findings PREMIER

Validating Findings DE019

Conclusions

Abstract #2

Study Design[a]

ACR20 Incidence in RF and ACPA Subgroups

HAQ-DI in RF and ACPA Subgroups

Conclusions

Abbreviations

Abbreviations (cont)